The use of mTOR inhibitors is potentially a hope in colon cancer treatment and the rational for association with other chemotherapeutic agents like irinotecan seems useful, but requires the identification of subgroups of patients that are most likely to respond. Here, MTOR is linked to malignant colon neoplasm.